217 related articles for article (PubMed ID: 18414714)
1. The use of budesonide in the treatment of autoimmune hepatitis in Canada.
Zandieh I; Krygier D; Wong V; Howard J; Worobetz L; Minuk G; Witt-Sullivan H; Yoshida EM
Can J Gastroenterol; 2008 Apr; 22(4):388-92. PubMed ID: 18414714
[TBL] [Abstract][Full Text] [Related]
2. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents.
Woynarowski M; Nemeth A; Baruch Y; Koletzko S; Melter M; Rodeck B; Strassburg CP; Pröls M; Woźniak M; Manns MP;
J Pediatr; 2013 Nov; 163(5):1347-53.e1. PubMed ID: 23810723
[TBL] [Abstract][Full Text] [Related]
3. Budesonide for the treatment of autoimmune hepatitis.
Snider KR; Potter TG
Ann Pharmacother; 2011 Sep; 45(9):1144-50. PubMed ID: 21878659
[TBL] [Abstract][Full Text] [Related]
4. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis.
Manns MP; Woynarowski M; Kreisel W; Lurie Y; Rust C; Zuckerman E; Bahr MJ; Günther R; Hultcrantz RW; Spengler U; Lohse AW; Szalay F; Färkkilä M; Pröls M; Strassburg CP;
Gastroenterology; 2010 Oct; 139(4):1198-206. PubMed ID: 20600032
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.
Inductivo-Yu I; Adams A; Gish RG; Wakil A; Bzowej NH; Frederick RT; Bonacini M
Clin Gastroenterol Hepatol; 2007 Jul; 5(7):799-802. PubMed ID: 17509945
[TBL] [Abstract][Full Text] [Related]
6. Budesonide in previously untreated autoimmune hepatitis.
Wiegand J; Schüler A; Kanzler S; Lohse A; Beuers U; Kreisel W; Spengler U; Koletzko S; Jansen PL; Hochhaus G; Möllmann HW; Pröls M; Manns MP
Liver Int; 2005 Oct; 25(5):927-34. PubMed ID: 16162148
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune hepatitis in southern Israel: a 15-year multicenter study.
Delgado JS; Vodonos A; Malnick S; Kriger O; Wilkof-Segev R; Delgado B; Novack V; Rosenthal A; Menachem Y; Melzer E; Fich A
J Dig Dis; 2013 Nov; 14(11):611-8. PubMed ID: 23815477
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies for autoimmune hepatitis.
Manns MP; Strassburg CP
Dig Dis; 2011; 29(4):411-5. PubMed ID: 21894012
[TBL] [Abstract][Full Text] [Related]
9. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus.
Chatur N; Ramji A; Bain VG; Ma MM; Marotta PJ; Ghent CN; Lilly LB; Heathcote EJ; Deschenes M; Lee SS; Steinbrecher UP; Yoshida EM
Liver Int; 2005 Aug; 25(4):723-7. PubMed ID: 15998421
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis.
Peiseler M; Liebscher T; Sebode M; Zenouzi R; Hartl J; Ehlken H; Pannicke N; Weiler-Normann C; Lohse AW; Schramm C
Clin Gastroenterol Hepatol; 2018 Feb; 16(2):260-267.e1. PubMed ID: 28126427
[TBL] [Abstract][Full Text] [Related]
11. Protocol of a prospective study for the combination treatment of Shu-Gan-jian-Pi decoction and steroid standard therapy in autoimmune hepatitis patients.
Chi XL; Xiao HM; Xie YB; Cai GS; Jiang JM; Tian GJ; Shi MJ; Wu SD; Zhao PT; Chen HJ
BMC Complement Altern Med; 2016 Dec; 16(1):505. PubMed ID: 27923369
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.
Richardson PD; James PD; Ryder SD
J Hepatol; 2000 Sep; 33(3):371-5. PubMed ID: 11019991
[TBL] [Abstract][Full Text] [Related]
13. Use of sirolimus in the treatment of refractory autoimmune hepatitis.
Chatrath H; Allen L; Boyer TD
Am J Med; 2014 Nov; 127(11):1128-1131. PubMed ID: 24979741
[TBL] [Abstract][Full Text] [Related]
14. Budesonide in the first line treatment of patients with autoimmune hepatitis.
Olivas I; Cobreros M; Londoño MC; Díaz-González Á
Gastroenterol Hepatol; 2022; 45(7):561-570. PubMed ID: 34923033
[TBL] [Abstract][Full Text] [Related]
15. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis.
Czaja AJ; Lindor KD
Gastroenterology; 2000 Nov; 119(5):1312-6. PubMed ID: 11054389
[TBL] [Abstract][Full Text] [Related]
16. Development of autoimmune hepatitis in primary biliary cirrhosis.
Gossard AA; Lindor KD
Liver Int; 2007 Oct; 27(8):1086-90. PubMed ID: 17845536
[TBL] [Abstract][Full Text] [Related]
17. Drug choices in autoimmune hepatitis: part A--Steroids.
Czaja AJ
Expert Rev Gastroenterol Hepatol; 2012 Sep; 6(5):603-15. PubMed ID: 23061711
[TBL] [Abstract][Full Text] [Related]
18. Azathioprine Monotherapy Is Equivalent to Dual Therapy in Maintaining Remission in Autoimmune Hepatitis.
McNally BB; Carey EJ
Dig Dis Sci; 2021 May; 66(5):1715-1719. PubMed ID: 32436124
[TBL] [Abstract][Full Text] [Related]
19. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome.
Efe C; Ozaslan E; Kav T; Purnak T; Shorbagi A; Ozkayar O; Berlot AH; Sökmensuer C; Muratori P
Autoimmun Rev; 2012 Mar; 11(5):330-4. PubMed ID: 22001521
[TBL] [Abstract][Full Text] [Related]
20. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis.
Hanouneh M; Ritchie MM; Ascha M; Ascha MS; Chedid A; Sanguankeo A; Zein NN; Hanouneh IA
Scand J Gastroenterol; 2019 Jan; 54(1):76-80. PubMed ID: 30650311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
